Neurophet and LADO Technology Form Joint Venture to Advance Brain Imaging Solutions in China

Neurophet, an AI-driven company specializing in brain disease solutions, has taken a strategic step toward entering the Chinese market through a new joint venture with Beijing LADO Technology Co., Ltd., a prominent Chinese software medical device provider. This collaboration, centered on Neurophet’s advanced PET image analysis software, Neurophet SCALE PET, leverages LADO’s established network and regulatory expertise, which will accelerate market entry and localization efforts across China. Neurophet SCALE PET offers an automated, quantitative approach to PET imaging, analyzing critical biomarkers linked to Alzheimer’s disease, such as amyloid beta and tau proteins, to aid in early diagnosis and patient care.

“Medical device companies face unique challenges within China’s rapidly evolving regulatory framework,” commented Jake Junkil Been, CEO of Neurophet. “By partnering with LADO, we aim to navigate these challenges and expand the reach of our brain analysis technology to address growing healthcare demands in China.” This partnership highlights a shared commitment to bringing cutting-edge brain imaging solutions to over 300 of China’s largest hospitals already using LADO’s nuclear medicine software.

Founded in 2016, Neurophet develops AI-based diagnostic tools and treatment planning software for brain diseases. With this partnership, the company solidifies its presence in the Chinese market, advancing its mission to support neurological health through innovative technology.